Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

5 results
10:20 AM, Apr 12, 2018  |  BC Extra | Financial News

Abpro planning $69M NASDAQ listing

to develop it to treat HER2-positive solid tumors in Orphan indications. ABP-201 targets VEGF and angiopoietin 2
ANG2; ANPT2). The company intends to develop that antibody to treat vascular diseases of the eye …
2:10 PM, Nov 27, 2017  |  BC Extra | Clinical News

Regeneron discontinues Eylea/nesvacumab combo

data from the trials before deciding on how to proceed with nesvacumab, a mAb against angiopoietin 2
ANG2; ANGPT2). He said Regeneron has not disclosed whether the candidate is in testing for other …
5:45 PM, Mar 24, 2016  |  BC Extra | Company News

Regeneron, Bayer strike another Eylea combo deal

wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Nesvacumab is a mAb against angiopoietin 2
ANG2 ; ANGPT2 ). Eylea is a human fusion protein that binds all forms of …
commercialization rights and will retain all profits from U.S. sales. According to the companies, targeting ANG2
4:53 PM, May 03, 2013  |  BC Extra | Top Story

Regeneron gains after 1Q13 results

targeting platelet derived growth factor (PDGF) for all indications including ophthalmology, and to antibodies targeting angiopoietin 2
ANG2 ; ANGPT2 ) for ophthalmology indications only. Sanofi will receive $10 million up front …
40 million in milestones for the PDGF antibodies and a $5 million milestone for the ANG2
5:33 PM, Dec 18, 2007  |  BC Extra | Company News

Pfizer to acquire CovX

CVX-045, a thrombospondin-1 ( TSP-1 ) mimetic in Phase I testing for cancer; CVX-060, an angiopoietin 2
Ang2) antagonist for which Phase I testing to treat cancer is expected to begin this month …